Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single-sequence, 2-period crossover study in healthy subjects. In this study, 20 subjects will be enrolled to allow at least 16 evaluable subjects. Subjects will receive a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) on Day 1 (Period 1) and on Day 29 (Period 2), and 600 mg efavirenz once a day from Days 15 through 42 (Period 2).


Clinical Trial Description

Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05909644
Study type Interventional
Source Biogen
Contact
Status Completed
Phase Phase 1
Start date July 5, 2023
Completion date August 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT03267732 - A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Phase 1
Completed NCT05040113 - A Study On Human Mass Balance And Biotransformation Phase 1
Completed NCT01433835 - Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers Phase 1
Completed NCT04029090 - A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects Phase 1
Completed NCT04586985 - Safety, Tolerability and Pharmacokinetics of FTX-6058 Phase 1
Completed NCT04481789 - Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) Phase 1
Completed NCT06107205 - Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects Phase 1
Completed NCT04629131 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults Phase 1
Recruiting NCT06063291 - Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects Phase 1
Completed NCT04203862 - A Study of NPC-22 in Healthy Adult Males Phase 1
Recruiting NCT05641181 - A Trial of CRB4101 in Healthy Subjects Phase 1
Completed NCT04521192 - Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects Phase 1
Completed NCT04400123 - A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers Phase 1
Completed NCT04811469 - Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults Phase 1
Completed NCT04291846 - A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects Phase 1
Completed NCT01364441 - Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects Phase 1
Completed NCT02691702 - Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers Phase 1
Recruiting NCT05334043 - Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects Phase 1
Completed NCT04493281 - Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects Phase 1
Completed NCT01376063 - Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects Phase 1